ERAS DEADLINE: Levi & Korsinsky Reminds Erasca, Inc. Investors of Upcoming Securities Class Action Deadline

Erasca's repeated preclinical comparisons to Revolution Medicines' RMC-6236 were allegedly improper and placed the company at risk of patent and trade secret violations, costing investors over $11 per share when the truth emerged. NEW YORK, July 1, 2026 /PRNewswire/ -- Levi & Korsinsky,...